Holdings of ARCH Venture Management, LLC
10 declared positions · as of Mar 31, 2026
Original filing · Ten largest lines: 100 % of the equity sleeve
Sector breakdown
- Unattributed 100.0 %
Titelia classification, company by company. The unattributed share stays visible.
Currency breakdown
- USD 100.0 %
The quoted currency of each line, as declared.
Country breakdown
- US 100.0 %
Shares computed on the equity sleeve.
| Rank | Country | Lines | Value | Share |
|---|---|---|---|---|
| 1 | US | 10 | 677.1M $ | 100.00 % |
Positions
| Rank | Company | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | Maze Therapeutics Inc | 4,120,053 | 123M $ | |
| 2 | Rapport Therapeutics Inc | 3,728,738 | 116.7M $ | |
| 3 | Vir Biotechnology Inc | 12,916,663 | 115.7M $ | |
| 4 | Erasca Inc | 7,091,557 | 114.7M $ | |
| 5 | Beam Therapeutics Inc | 4,540,132 | 108.2M $ | |
| 6 | Lyell Immunopharma Inc | 3,247,162 | 65.1M $ | |
| 7 | Generate Biomedicines Inc | 1,944,426 | 24.3M $ | |
| 8 | 10X Genomics Inc | 217,834 | 4.6M $ | |
| 9 | Gossamer Bio Inc | 8,055,916 | 2.6M $ | |
| 10 | Q32 Bio Inc | 320,482 | 2.1M $ |